Review





Similar Products

anti hla dr ab  (ATCC)
95
ATCC anti hla dr ab
Anti Hla Dr Ab, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/L243/pmc12198103-101-8-11
Average 95 stars, based on 1 article reviews
anti hla dr ab - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
hla dra polyclonal rabbit ab  (Boster Bio)
90
Boster Bio hla dra polyclonal rabbit ab
AHR and ARNT regulate basal <t>HLA-II</t> expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and <t>HLA-DRA</t> were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and <t>polyclonal</t> anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control
Hla Dra Polyclonal Rabbit Ab, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/Anti-HLA-DR%2FHLA-DRA+Antibody+Picoband/pmc13032475-81-24-28
Average 90 stars, based on 1 article reviews
hla dra polyclonal rabbit ab - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
fitc anti human hla dr  (Elabscience Biotechnology)
94
Elabscience Biotechnology fitc anti human hla dr
AHR and ARNT regulate basal <t>HLA-II</t> expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and <t>HLA-DRA</t> were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and <t>polyclonal</t> anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control
Fitc Anti Human Hla Dr, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/FITC+Anti-Human+HLA-DR+Antibody/pm41578166-106-20-27
Average 94 stars, based on 1 article reviews
fitc anti human hla dr - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
anti human hla dr  (Elabscience Biotechnology)
94
Elabscience Biotechnology anti human hla dr
AHR and ARNT regulate basal <t>HLA-II</t> expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and <t>HLA-DRA</t> were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and <t>polyclonal</t> anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control
Anti Human Hla Dr, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/FITC+Anti-Human+HLA-DR+Antibody/pmc12830368-108-15-18
Average 94 stars, based on 1 article reviews
anti human hla dr - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
pe anti human hla dr antibody  (Elabscience Biotechnology)
94
Elabscience Biotechnology pe anti human hla dr antibody
Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and <t>HLA-DR</t> + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.
Pe Anti Human Hla Dr Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/PE+Anti-Human+HLA-DR+Antibody/pmc12794431-14-0-6
Average 94 stars, based on 1 article reviews
pe anti human hla dr antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
e ab f1111d  (Elabscience Biotechnology)
94
Elabscience Biotechnology e ab f1111d
Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and <t>HLA-DR</t> + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.
E Ab F1111d, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/PE+Anti-Human+HLA-DR+Antibody/pmc12794431-14-8-6
Average 94 stars, based on 1 article reviews
e ab f1111d - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
apc anti human hla dr  (Elabscience Biotechnology)
93
Elabscience Biotechnology apc anti human hla dr
Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and <t>HLA-DR</t> + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.
Apc Anti Human Hla Dr, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/APC+Anti-Human+HLA-DR+Antibody/pmc12627561-404-92-116
Average 93 stars, based on 1 article reviews
apc anti human hla dr - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
hla dr antibodies  (Elabscience Biotechnology)
94
Elabscience Biotechnology hla dr antibodies
Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and <t>HLA-DR</t> + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.
Hla Dr Antibodies, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hla+dr+ab/PE+Anti-Human+HLA-DR+Antibody/pm40728809-72-19-21
Average 94 stars, based on 1 article reviews
hla dr antibodies - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


AHR and ARNT regulate basal HLA-II expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma

doi: 10.1186/s13046-026-03673-y

Figure Lengend Snippet: AHR and ARNT regulate basal HLA-II expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Article Snippet: The following primary antibodies were used: AHR Rabbit mAb (clone D5S6H, CST #83200, RRID: AB_2800011), ARNT Rabbit mAb (clone D28F3, CST #5537, RRID: AB_10694232), HLA-DRA polyclonal Rabbit Ab (Boster #A01195), β-Tubulin Mouse mAb (clone C66, Abmart # M20005 , RRID: AB_2920648), and β-Actin Rabbit mAb (clone 13E5, CST #4970, RRID: AB_2223172).

Techniques: Expressing, Western Blot, Over Expression, Control, Flow Cytometry, Plasmid Preparation, Generated

Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and HLA-DR + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.

Journal: iScience

Article Title: Hypoxic-immune axis orchestrates metastatic dissemination via HIF isoform imbalance in pancreatic neuroendocrine tumors

doi: 10.1016/j.isci.2025.114340

Figure Lengend Snippet: Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and HLA-DR + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.

Article Snippet: PE Anti-Human HLA-DR Antibody [L243] , Elabscience , E-AB-F1111D.

Techniques: Mutagenesis, Software, Fluorescence

Tregs, CD8 + T cells, and HLA-DR + cells in KRAS G12C -mutated PNETs (A) Flow cytometry plots and fluorescence intensity histograms demonstrate elevated CD4 + T cell proportions in KRAS G12C patient blood samples compared to wild-type KRAS tumors and healthy controls. (B) Quantification shows a significant enrichment of CD25 + T cells in KRAS G12C patients, surpassing both wild-type KRAS tumors and normal controls. (C) Quantitative data and histogram overlays confirm a substantial increase in FoxP3 + T cells frequency in KRAS G12C patients, with levels moderately elevated compared to wild-type KRAS and significantly higher than healthy individuals. (D) A slight decrease in CD8 + T cell frequency in KRAS G12C samples relative to wild-type KRAS, with levels significantly lower than those in healthy individuals (E) A moderate reduction in HLA-DR + cell frequency in KRAS G12C patients compared to wild-type KRAS, alongside a marked suppression relative to healthy controls.

Journal: iScience

Article Title: Hypoxic-immune axis orchestrates metastatic dissemination via HIF isoform imbalance in pancreatic neuroendocrine tumors

doi: 10.1016/j.isci.2025.114340

Figure Lengend Snippet: Tregs, CD8 + T cells, and HLA-DR + cells in KRAS G12C -mutated PNETs (A) Flow cytometry plots and fluorescence intensity histograms demonstrate elevated CD4 + T cell proportions in KRAS G12C patient blood samples compared to wild-type KRAS tumors and healthy controls. (B) Quantification shows a significant enrichment of CD25 + T cells in KRAS G12C patients, surpassing both wild-type KRAS tumors and normal controls. (C) Quantitative data and histogram overlays confirm a substantial increase in FoxP3 + T cells frequency in KRAS G12C patients, with levels moderately elevated compared to wild-type KRAS and significantly higher than healthy individuals. (D) A slight decrease in CD8 + T cell frequency in KRAS G12C samples relative to wild-type KRAS, with levels significantly lower than those in healthy individuals (E) A moderate reduction in HLA-DR + cell frequency in KRAS G12C patients compared to wild-type KRAS, alongside a marked suppression relative to healthy controls.

Article Snippet: PE Anti-Human HLA-DR Antibody [L243] , Elabscience , E-AB-F1111D.

Techniques: Flow Cytometry, Fluorescence